TAYLOR LEBLANC: Open Payments
NPI 1366912537 · ALBANY, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$23,218 in 89 payments from 12 companies in 2025. Trend: 2023 $7,739 · 2024 $16,228 · 2025 $23,218
Speaker / faculty: $16,645Consulting: $3,188Travel & lodging: $1,886Food & beverage: $1,500
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 36 | $12,829 |
| ABBVIE INC. | 27 | $9,706 |
| Braeburn Inc. | 8 | $139 |
| Corcept Therapeutics | 1 | $122 |
| Janssen Pharmaceuticals, Inc | 3 | $89 |
| Sumitomo Pharma America, Inc. | 1 | $79 |
| E.R. Squibb & Sons, L.L.C. | 4 | $75 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| Neurocrine BioSciences, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
Products named: CAPLYTA, VRAYLAR, BRIXADI, Korlym, GEMTESA, COBENFY, INVEGA SUSTENNA, FANAPT.
Industry payments across GA — which companies pay providers there.
